


Construction of drug development platform of disease-specific degradation by CANDDY (FuturedMe Inc.)



City	Year of Establishment	Founder	Website
Chuo-ku, Tokyo	2018	Etsuko Miyamoto-Sato	https://futuredme.com/jp/#secMV

Partner VC	Latest round of Fundraising	Valuation
KSP, Inc.	Series A	Non-Disclosure

Contact Information :

tel : 81-4-7197-6230

Website : <https://futuredme.com/jp/#secMV>

○ Business Plan

In the era of precision medicine, genomic medicine needs to solve the problem (pain) that even if the causative molecule (target) of a disease is identified, there is no therapeutic drug for the target. To this end, we will raise the barrier to entry for CANDDY, the next-generation degradative drug discovery technology, and build a disease-specific degradative drug development platform that will establish a differentiated prototype, expand the market, and reduce side effects.

○ Research Outline

In this research and development, we will construct the "Immune CANDDY Platform" as a degradative drug development technology that does not act on normal cells but can target degradation only in cancer cells due to immunoproteasome selectivity.

- ① Shows the difference in the degradation index (DC50) between normal cells and diseased cells.
- ② Shows the degradation of naturally denatured proteins.
- ③ Showing the POC of the initial prototype of the CANDDY molecule.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2023~2025FY	JPY 61 million	Worldwide, especially in the US

○ International collaborative technology demonstration

- Contract with local partners

STS phase plans to have a Japanese pharmaceutical company become an expert and obtain a "letter of interest" from PCA phase to realize a partnership. We will also be in contact with pharmaceutical companies in the United States or Europe etc., and plan to partner with overseas pharmaceutical companies after graduation.